| #特殊劑型：不建議磨粉、管灌藥品 |
Active mild to moderate inflammatory bowel disease (ulcerative colitis and Crohn's disease)
#仿單變更2020
Mezavant XL tab is a Multi-MatriX (MMX) system formulation of mesalamine. Mesalamine (5-aminosalicylic acid) is the active component of sulfasalazine; the specific mechanism of action of mesalamine is unknown; however, it is thought to exhibit a localized effect on GI mucosa by inhibiting cyclooxygenase and 5-lipoxygenase, thereby down-regulating the production of inflammatory prostaglandins.
Absorption: by the oral route approximately 21-22%; 74% of the administered dose remains within the terminal ileum and colon, being available to exert a topical anti inflammatory effect. Metabolism: Hepatic and via GI tract to inactive metabolite N-acetyl-5-aminosalicylic acid; and is primarily excreted by the kidney as the metabolite and unchanged drug.
Hypersensitivity to mesalamine, aminosalicylates, salicylates, or any component of the formulation. Severe liver or renal impairment(GFR <30ml/min/1.73m2) .
B (Mesalazine should only be used during pregnancy if the potential benefit outweighs the possible risk.)
Enters breast milk/use caution
Headache, flatulence, nausea.Papilledema(曾出現有顱內壓上升的報告) <20201113>. SJS, TEN<20220610>
For maintenance of remission: 2.4g (two tablets) once daily with a meal. Swallow whole, do not crush or chew.